Accelerating Drug Discovery through Knowledge Sharing

Modern drug discovery faces high rates of clinical attrition, more challenging therapeutic targets, increasing molecular complexity, and rising research and development costs. These challenges are not only due to greater scientific risk, but also the way that organizations leverage drug discovery knowledge. It is believed that effective knowledge sharing-both tools and culture-is core infrastructure that can increase the probability of success. Readily accessible knowledge hubs built on familiar software (OneNote + SharePoint → "OnePoint") and enterprise wikis (Pfizerpedia) scale well because information capture happens during daily work, not outside it. Chemistry-focused platforms, such as Roche's system based on brief "knowledge slides," turn tacit insights into reusable design precedent. At AstraZeneca, a MediaWiki-based Compound Design Database (CDD) tied to quantitative structure-activity relationship (QSAR) models and explicit tracking of the design-make-test-analyze (DMTA) cycle cut idea-to-compound time by 50% through synchronizing design and synthesis. Codifying heuristics (e.g., Drug Guru's 186 rule-encoded transformations) institutionalizes expert playbooks while training newer chemists. Furthermore, it is discussed how the durable impact of knowledge sharing depends on human systems (networks, incentives, curated "push" updates, and embedded workflows), as well as curated external knowledge streams that supply early competitive signals and context for action.